慢性心不全におけるC型ナトリウレチンペプチドの心筋内産生
Paul R Kalra1, Jonathon R Clague, Aidan P Bolger
1Clinical Cardiology, National Heart and Lung Institute, London, UK. p.kalra@ic.ac.uk
Circulation
|February 5, 2003
まとめ
C型ナトリウレチンペプチド (CNP) は,慢性心不全 (CHF) の患者の心臓で生成されます. この研究では,心臓のCNP生成が示され,それが心臓病の新たな媒介者かもしれないことを示唆しています.
科学分野:
- 心臓病学 心臓病学
- エンドクリノロジー エンドクリノロジー
- 分子生物学は分子生物学である.
背景:
- C型ナトリウレチンペプチド (CNP) は,血管内皮によって生成される血管拡張剤です.
- 慢性心不全 (CHF) におけるその役割は十分に理解されていません.
- CNPは,心房および脳のナトリウレティックペプチドと特性を共有しています.
研究 の 目的:
- CHFの患者において,心臓がCNPを産生するかどうかを調査する.
- CHFにおける心筋中枢神経核膜細胞の生成の仮説を評価する.
主な方法:
- 9人のCHF患者の大動脈根と冠動脈陰道 (CS) の血CNPとBNPレベルを測定した.
- 分析のために心経キャセテリゼーションと放射性免疫測定法を使用しました.
- 筋動脈の生成に対する陽性対照としてBNPを評価した.
主要な成果:
- プラズマのCNP濃度の有意な29%の上昇が,大動脈からCSに観察されました (P=0.035).
- BNPレベルは,大動脈からCSに57%増加した (P=0.01).
- 冠動脈副鼻腔のCNPレベルは,肺毛細血管の圧と相関している (r=0.82,P=0.007).
結論:
- 慢性心不全の患者では,心臓がC型ナトリウレチンペプチドを産生する.
- CNPは,CHFにおいて心臓内の重要な局所的なメディエーターとして機能する可能性があります.
- 心不全におけるCNPの病理生理学的役割を完全に解明するには,さらなる研究が必要である.
関連する概念動画
01:17Pathophysiology of Heart Failure
4.8K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.8K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.9K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.9K
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
765
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
765
01:29Heart Failure II: Pathophysiology
1.9K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.9K
01:30Cardiomyopathy II: Dilated Cardiomyopathy
790
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
790
01:29Cardiomyopathy VI: Nursing Management
481
Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
481